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Human immunodeficiency virus (HIV)-infect-ed patients are at an increased risk of devel-oping lymphoma compared with the general 
population. In the highly active antiretroviral therapy 
(HAART) era several studies suggest a declining inci-
dence of acquired immunodeficiency disease syndrome 
(AIDS)-related lymphoma; nevertheless Burkitt lym-
phoma (BL) remains very frequent, accounting for 25% 
to 40% of all AIDS-related lymphoma.1-3 Before the 
HAART era, standard chemotherapy regimens were 
preferred for HIV-infected patients due to the high pro-
portion of complications and deaths.2 The introduction 
of HAART into clinical practice has improved AIDS-
related non-Hodgkin lymphoma (NHL) response rates 
and survival in general, with the only exception being 
BL. For this reason, several investigators have suggested 
that more aggressive treatment protocols such as those 
used for HIV-negative patients should be incorporated 
for this subset of patients.2,4-7 In addition, the benefit of 
concomitant use of HAART during chemotherapy is 
not well established.4,5,8,9
AIDS-related sinonasal Burkitt lymphoma 
successfully treated with intensive 
chemotherapy regimen and high active 
antiretroviral therapy
Gustavo Werutsky,a Gisele Pereira de Carvalho,a Vinicius Duval da Silva,b Bernardo Garicocheaa 
from the aDepartment of medical oncology and bDepartment of Pathology, são Lucas hospital, Pontifical Catholic university of rio Grande 
do sul, Porto alegre, Brazil
Correspondence: Gustavo Werutsky, mD · Department of medical oncology, são Lucas hospital, Pontifical Catholic university of rio Grande 
do sul (PuCrs), 6690/228 ipiranga av., Porto alegre, 90610-000 Brazil · gwerutsky@hotmail.com · accepted: march 2011
hematol oncol stem Cel ther 2011; 4(1): 41-44
Doi: 10.5144/1658-3876.2011.41
Burkitt lymphoma (BL) is the second most common aiDs-related lymphoma. Primary sinonasal BL in hiV 
patients is extremely rare and treatment data in this subset of patients is almost nonexistent. recently, 
a few studies reported promising results treating hiV-associate BL with an intensive chemotherapy regi-
men. the use of highly active antiretroviral therapy (haart) concomitantly with chemotherapy seems 
to improve patient outcomes, but this topic is still controversial due to potential drug interactions. We 
report a case of a 29-year old woman diagnosed with aiDs presenting with symptoms of chronic sinusitis. 
subsequent investigation by Ct scan and endoscopic biopsy discovered a sinonasal BL in an early stage. 
the patient was treated with intensive chemotherapy and haart and achieved a complete remission and 
long-term immunologic recovery. this case report describes a rare entity whose natural history, treatment 
and prognosis is infrequently characterized in the medical literature.
AIDS-related BL typically presents as an aggressive 
disseminated disease frequently involving the bone mar-
row, extra nodal sites and the central nervous system.3,10 
HIV-associated BL affecting the sinonasal tract is an 
extremely rare occurrence, and in fact, there are only a 
few case reports in the literature where the treatment 
strategy is not clearly described. We report a case of 
AIDS-related BL presenting in the sinonasal tract—a 
rare entity whose natural history, treatment and prog-
nosis is infrequently characterized in the medical litera-
ture—successfully treated with intensive chemotherapy 
regimen and HAART. 
CASE
A 29-year-old woman was diagnosed with AIDS on 
November 2006 with a baseline CD4 count of 42 cells/
µL and HIV RNA 4500 000 copies/mL. The patient 
started HAART treatment (lamivudine and zidovu-
dine (Biovir), atazanavir/ritonavir) and trimethoprim/
sulfamethoxazole for opportunistic infection prophy-
laxis. A few months later, she related a history of nasal 
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obstruction and mucopurulent nasal discharge that was 
treated as sinusitis without resolution. CT scans of the 
sinuses showed lesions with soft-tissue density in the 
right maxillary, ethmoid and sphenoid sinuses involving 
the nasal cavity and nasopharynx (Figure 1). Chronic 
sinusitis, especially of a fungal etiology, with concomi-
tant nasal polypoid disease was suspected.
The patient underwent an endoscopic sinonasal 
surgery in April 2007 showing polypoid lesions in the 
nasal cavity and a mass occupying the paranasal sinus. 
A biopsy from the bilateral maxillary and ethmoid sinus 
was performed. Results for a mycological test and acid-
fast bacilli (AFB) smear were negative. The histological 
examinations showed a “starry sky” appearance sugges-
tive of BL (Figure 2). The diagnosis was confirmed by 
the typical Burkitt’s immunophenotype CD10+, bcl6+, 
bcl2- and Ki67 proliferation index > 99%. Cytogenetics 
analysis not performed.
Staging procedures, including brain CT scan and 
cerebrospinal fluid cytology, did not show any evi-
dence of disease outside of the sinonasal area (Ann 
Arbor stage IE) and was scored as low risk by the 
International Prognostic Index (IPI). The patient 
had a good performance status (WHO 0) and a CD4 
count of 240 cells/µL while still using HAART, just 
before chemotherapy.
In July 2007 she started the treatment with an in-
tensive chemotherapy regimen consisting in alternating 
cycles of cyclophosphamide, vincristine, doxorubicin, 
high-dose methotrexate (CODOX-M) and IVAC (in-
cluding 8 doses of cytarabine/methotrexate intrathecal 
prophylaxis) for a total of four cycles with maintenance 
of HAART during the treatment.11 During the first 
cycle administration the patient experienced febrile 
neutropenia (grade IV) requiring hospitalization. After 
leukocyte recovery the CODOX-M regimen was com-
pleted. The alternating cycle IVAC started on August 
2007 when the patient was again hospitalized due to 
a new episode of febrile neutropenia (grade IV) and 
diarrhea (grade II). Next, a dose of CODOX-M was 
administered on September 2007 without any serious 
adverse event and the last cycle of IVAC was adminis-
tered on October 2007 when the patient repeat a epi-
sode of febrile neutropenia (grade IV) with complete 
recover in hospital.
The post-treatment CT scan on November 2007 
showed partial regression of lesions with persistent mu-
cosal thickening in the ethmoid, sphenoid and maxillary 
sinuses. Further nasal endoscopy showed no suspicious 
lesions. The patient was considered to have achieved a 
complete response and remain free of disease for the 
last 28 months. 
Figure 1. Sinus CT scans revealed lesions with soft-tissue density 
in the right maxillary, ethmoid and sphenoid sinuses involving the 
nasal cavity and nasopharynx.
Figure 2. Histologic examination in a standard H&e stain reveals 
medium-size lymphoid cells with high proliferative activity and 
phagocytic macrophages. H&e×100. 
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DISCUSSION
Despite being an uncommon type of lymphoma in im-
munocompetent adults, BL is the second most common 
HIV-associated lymphomas. The possible mechanisms 
and pathways responsible for the development of this 
disease are not fully understood, but chronic B-cell stim-
ulation induced by HIV itself, as well as by other co-in-
fecting viruses, such as Epstein Barr virus (EBV) could 
provoke genetic aberrations, specially involving c-MYC 
translocation.1,2 NHL of the sinonasal tract includes 
lymphomas of B-cell lineage, T-cell lineage, and NK/T-
cell lineage. Nasal cavity lymphomas are predominantly 
of NK/T-cell type and most B-cell lymphomas occur 
in the paranasal sinuses whereas the diffuse large B-cell 
lymphoma is the most common type. Primary sinona-
sal BL is very rare and actually the real prevalence of 
this neoplasm in HIV patients is unknown. The clinical 
presentation of sinonasal lymphomas usually is nasal 
obstruction or other nonspecific symptoms consistent 
with chronic rhinosinusitis. Furthermore, CT scans are 
sometimes unable to definitively discriminate tumors 
from other inflammatory processes. Benign polyps are 
frequently found adjacent to abnormal appearing mass, 
therefore, all suspicious findings should be biopsied.12 
HIV testing is warranted in all patients who develop 
BL, including patients with stage I disease. 
Several studies showed that the risk for develop-
ment of HIV-associate NHL increases as the CD4 cell 
count falls and viral replication rises.2,3,13 In contrast, BL 
is often diagnosed earlier during the natural course of 
HIV infection or shortly after confirmation of HIV in-
fection suggesting that it occurs in less severe immuno-
deficiency states; in fact at diagnosis the median CD4 
counts are higher compared with HIV-diffuse large cell 
lymphoma.2,4,8,13
Prior to the prewidespread use of HAART, treatment 
of HIV-BL was based on reduced-dose chemotherapy 
regimens, such as methotrexate, bleomycin, Adriamycin 
(doxorubicin), cyclophosphamide, Oncovin (vincris-
tine), dexamethasone (M-BACOD) due to the better 
safety profile and comparable outcomes with standard 
regimens.8 However in the HAART era, reduction of 
opportunist infection and better tolerance to treatment 
improves dramatically the prognosis of those patients. 
HIV-related diffuse large-cell lymphoma survival im-
proves from 8.3 months in the pre-HAART era to 43.2 
months in the HAART era with standard chemothera-
py, such outcomes are comparable to non-HIV infected 
population. Interestingly, the prognosis of patients with 
HIV-BL remained poor, mainly because the continued 
use of standard-dose chemotherapy.8 Recently, several 
investigators have suggested that intensive chemothera-
py regimens with concomitant HAART may be more 
efficacious in this group of patients with acceptable tox-
icity.4,7 In fact, the patient presented in our case report 
received an intensive chemotherapy regimen (CODOX-
M/IVAC) concomitantly with HAART achieving a 
CR and remaining relapse-free for more than 2 years. 
Two retrospective studies evaluating this regimen in 
patients with HIV-BL found comparable results in 
terms of CR and EFS at 2 years to those seen in general 
population, and also a satisfactory immunological recov-
ery after 6 months following chemotherapy.5,14 Studies 
evaluating the use of intensive chemotherapy protocols 
and HAART in patients with HIV-BL showed a treat-
ment-related mortality of 10% to 17%, which is similar 
to studies in general population, in addition to that fac-
tors such CD4 <100 cell/µL count, ≤2 performance sta-
tus and a high-risk classification by international prog-
nostic index score (IPI) at baseline were associate with 
high toxicity and poor survival.2,4-7,15
Though rituximab has shown promise in improv-
ing outcomes for patients with BL, the safety profile for 
used in HIV patients is controversial. Short series and 
retrospective studies associates rituximab with prolong 
immunosuppression and late deaths, mainly in patients 
with low CD4 counts.2,6 The association of rituximab 
with intensive chemotherapy in AIDS-related lympho-
ma should be evaluated in prospective trials.
In conclusion, our case report shows that the treat-
ment of HIV-associated BL with intensive chemo-
therapy regimen concomitantly with HAART can be 
feasible and successful. The identification of clinical 
and hematological markers of treatment tolerance and 
response is needed. HIV patients with symptoms of 
allergic rhinitis or chronic sinusitis should be carefully 
evaluated and a high level of suspicion for malignancies 
is mandatory. Due to the rapid evolution of BL, early 
diagnosis and prompt treatment are key factors for bet-
ter outcome. 
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